Amgen’s product sales in the fourth quarter are expected to have been driven by strong volume growth of Evenity ... Consistent label expansions in newer metastatic and adjuvant indications ...
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
The Business Research Company's Evenity Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...
Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...
Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
a hit to his reputation and a decrease in his brand's value before his contract renegotiation with the record label this year. The suit added that UMG "understood the recording's inflammatory and ...
* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...
Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies. Per the Earnings ...
Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies. Per the Earnings ...
Targeting the lowest performers may be logical for the companies' bottom lines, but the publicity surrounding layoffs can give those a negative label that can compound the difficulties of being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results